In a major breakthrouh for India amid the long going battle against novel Coronavirus, a study conducted by Indian Council of Medical Research (ICMR) shows Indigenous Covid-19 vaccine COVAXIN, made by Bharat Biotech, neutralises against multiple variants of SARS-CoV-2 and effectively neutralises the double mutant strain as well.
ICMR in a statement on Wednesday said, "ICMR study shows COVAXIN neutralises against multiple variants of SARS-CoV-2 and effectively neutralises the double mutant strain as well."
ALSO READ | Covishield Vaccine Price: Serum Institute Fixes Price For State Govt & Private Hospitals
<blockquote class="twitter-tweet" data-partner="tweetdeck"><p lang="en" dir="ltr">ICMR study shows COVAXIN neutralises against multiple variants of SARS-CoV-2 and effectively neutralises the double mutant strain as well: Indian Council of Medical Research (ICMR) <a href="https://news.abplive.com/health/lancet-study-says-bharat-biotech-s-covaxin-safe-to-use-1447855">#COVID19</a> <a >pic.twitter.com/QDM6UcaJkg</a></p>— ANI (@ANI) <a >April 21, 2021</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>
Covaxin has received Emergency Use Authorizations (EUAs) for COVID-19 treatment in India and in several countries across the globe.
Earlier this month, the Centre said the current production capacity of indigenously developed Covaxin vaccine will be doubled by May-June and then increased nearly six to seven fold by July - August, adding it is expected to reach nearly 10 crore doses per month by September.
Union Finance Minister Nirmala Sitharaman had recently approved Rs 4,567.50 crore advance amount to Serum Institute of India (SII) and Bharat Biotech to ramp up vaccine production against coronavirus.